This content is accessible only to 2020 ASCRS Virtual Annual Meeting attendees. If you attended the virtual meeting, please log in with the account associated with your virtual meeting registration. To log in, click the teal "Login" button in the upper right-hand corner of this page.
Outcomes of unilateral refractive lens exchange (RLE) with implantation of a trifocal intraocular lens (IOL) are limited. The purpose of this study was to evaluate the visual outcomes and patient satisfaction following unilateral implantation of a diffractive trifocal IOL in the non-dominant eye of hyperopic patients with presbyopia.
This is a single-center, retrospective case series. Hyperopic presbyopic patients who underwent unilateral femtosecond-laser assisted RLE with implantation of a diffractive trifocal IOL (Alcon Panoptix) in the non-dominant eye were evaluated. The contralateral eye was corrected with keratorefractive surgery if needed. Inclusion criteria were hyperopia over +1.00 D and presbyopia (J3 or worse). Primary outcome measures were uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), and uncorrected near visual acuity (UNVA). Secondary outcomes were spherical equivalent (SE) and patient questionnaire. Three and six months data will be evaluated.
At 1 month, preliminary results from 15 eyes of 15 patients (average age 53.2 ± 4.1 years) showed a change in monocular UDVA from 0.50 ± 0.25 logMAR preoperatively to 0.11 ± 0.21 logMAR postoperatively (p <0.01). UIVA and UNVA improved postoperatively to 0.05 ± 0.12 logMAR and 0.08 ± 0.10 logMAR, respectively (p < 0.005). 100% (15/15) of eyes were within ±1.00 D of emmetropia and 87% (13/15) of eyes achieved an UNVA of J2 (snellen 20/30) or better. There were no intraoperative complications and no IOL exchange was required. More cases will be reviewed and final outcomes including spectacle independence, visual disturbances, and patient satisfaction will be assessed after 3 and 6 months.
Unilateral RLE with a diffractive trifocal IOL (Alcon Panoptix) in hyperopic presbyopic patients is safe and effective. Final conclusions will be made after 3 and 6 months.